[15] In July 2024, CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines.
[16] In June 2024, the European Commission's Health Emergency Preparedness and Response Authority (HERA) signed a four-year contract with CSL Seqirus to secure 665,000 pre-pandemic vaccines with a provision for a further 40 million doses of avian flu vaccines.
These fifteen countries[17][18] are: Denmark, Latvia, France, Cyprus, Lithuania, Malta, the Netherlands, Austria, Portugal, Slovenia, Finland, Greece, Ireland, Iceland, and Norway.
[19] In January 2020, the U.S. Food and Drug Administration (FDA) approved Audenz, an adjuvanted influenza A (H5N1) monovalent vaccine.
[2][12] In November 2013, the U.S. Food and Drug Administration (FDA) approved an experimental H5N1 bird flu vaccine to be held in stockpiles.
"[34] However, "pre-pandemic vaccines" have been created; are being refined and tested; and do have some promise both in furthering research and preparedness for the next pandemic.